Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Sancuso
Overview
What is Sancuso?
Sancuso contains granisetron, which is a serotonin-3 (5-HT) receptor antagonist. Chemically it is 1-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide with a molecular weight of 312.4. Its empirical formula is CHNO, while its chemical structure is:
Granisetron is a white to off-white solid that is insoluble in water. Sancuso is a thin, translucent, matrix-type transdermal patch that is rectangular-shaped with rounded corners, consisting of a backing, the drug matrix and a release liner.
What does Sancuso look like?
What are the available doses of Sancuso?
Transdermal System: 52 cm patch containing 34.3 mg of granisetron delivering 3.1 mg per 24 hours ()
What should I talk to my health care provider before I take Sancuso?
How should I use Sancuso?
Sancuso (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.
The transdermal system (patch) should be applied to clean, dry, intact healthy skin on the upper outer arm. Sancuso should not be placed on skin that is red, irritated, or damaged.
Each patch is packed in a pouch and should be applied directly after the pouch has been opened.
The patch should not be cut into pieces.
What interacts with Sancuso?
Sorry No Records found
What are the warnings of Sancuso?
Sorry No Records found
What are the precautions of Sancuso?
Sorry No Records found
What are the side effects of Sancuso?
Sorry No records found
What should I look out for while using Sancuso?
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.
What might happen if I take too much Sancuso?
There is no specific antidote for granisetron overdosage. In the case of overdosage, symptomatic treatment should be given.
Overdosage of up to 38.5 mg of granisetron hydrochloride, as a single intravenous injection, has been reported without symptoms or only the occurrence of a slight headache.
In clinical trials there were no reported cases of overdosage with Sancuso.
How should I store and handle Sancuso?
Store at 20˚ to 25˚C (68˚ to 77˚F)Sancuso (Granisetron Transdermal System) is supplied as a 52 cm patch containing 34.3 mg of granisetron. Each patch is printed on one side with the words "Granisetron 3.1 mg/24 hours". Each patch is packaged in a separate sealed foil-lined plastic pouch.Sancuso is available in packages of 1 (NDC 42747-726-01) patch.Sancuso (Granisetron Transdermal System) is supplied as a 52 cm patch containing 34.3 mg of granisetron. Each patch is printed on one side with the words "Granisetron 3.1 mg/24 hours". Each patch is packaged in a separate sealed foil-lined plastic pouch.Sancuso is available in packages of 1 (NDC 42747-726-01) patch.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Granisetron is a selective 5-hydroxytryptamine (5-HT) receptor antagonist with little or no affinity for other serotonin receptors, including 5-HT 5-HT, 5-HT, 5-HT; for alpha-, alpha-, or beta-adrenoreceptors; for dopamine-D; or for histamine-H; benzodiazepine; picrotoxin or opioid receptors.
Serotonin receptors of the 5-HT type are located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. During chemotherapy that induces vomiting, mucosal enterochromaffin cells release serotonin, which stimulates 5-HT receptors. This evokes vagal afferent discharge, inducing vomiting. Animal studies demonstrate that, in binding to 5-HT receptors, granisetron blocks serotonin stimulation and subsequent vomiting after emetogenic stimuli such as cisplatin. In the ferret animal model, a single granisetron injection prevented vomiting due to high-dose cisplatin or arrested vomiting within 5 to 30 seconds.
Non-Clinical Toxicology
Sancuso is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.The use of granisetron in patients may mask a progressive ileus and/or gastric distention caused by the underlying condition.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).